Phase II study of loading-dose ibandronate treatment in patients with breast cancer and bone metastases suffering from moderate to severe pain

Basit Öğe Kaydı
dc.contributor.authorAltundag K.
dc.contributor.authorDizdar O.
dc.contributor.authorOzsaran Z.
dc.contributor.authorOzkok S.
dc.contributor.authorSaip P.
dc.contributor.authorEralp Y.
dc.contributor.authorKomurcu S.
dc.contributor.authorKuzhan O.
dc.contributor.authorOzguroglu M.
dc.contributor.authorKarahoca M.
dc.date.accessioned2019-10-26T21:51:22Z
dc.date.available2019-10-26T21:51:22Z
dc.date.issued2012
dc.departmentEge Üniversitesien_US
dc.description.abstractBackground: The aim of this study was to determine the efficacy and safety of loading-dose intravenous (i.v.) ibandronate in women with breast cancer and bone metastases. Patients and Methods: In this prospective, phase II, open-label study, 13 women with breast cancer, bone metastases, and moderate/severe bone pain received ibandronate 6 mg/day (i.v. loading-dose 15 min infusion over 3 consecutive days) with follow-up until day 14. Endpoints included pain response (primary), duration until pain response, analgesic use, Karnofsky index, safety (including hematologic, biochemical, and urine examinations), and adverse events. Results: Pain intensity decreased on days 7 and 14 versus day 1 (mean visual analogue scale score: 3.2 ± 2.2 and 3.0 ± 2.1 versus 6.1 ± 0.9, respectively; p < 0.01 for both). Mean time to pain response was 8.2 ± 3.3 days. Mean rate of analgesic use decreased (69.2%, 16.7% and 15.4% on days 1, 7 and 14, respectively). Mean Karnofsky index score increased (80.8 ± 13.1 and 80.8 ± 13.2, on days 7 and 14 versus 77.7 ± 11.7 on day 1; p < 0.05 on both days). Conclusion: Bone pain and analgesic use decreased in women with breast cancer and bone metastases following loadingdose i.v. ibandronate which was well-tolerated with no renal safety concerns. Copyright © 2012 S. Karger AG, Basel.en_US
dc.identifier.doi10.1159/000338369en_US
dc.identifier.endpage258en_US
dc.identifier.issn0378-584X
dc.identifier.issue5en_US
dc.identifier.pmid22868504en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.startpage254en_US
dc.identifier.urihttps://doi.org/10.1159/000338369
dc.identifier.urihttps://hdl.handle.net/11454/18796
dc.identifier.volume35en_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.relation.ispartofOnkologieen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectBisphosphonateen_US
dc.subjectBone metastasesen_US
dc.subjectBone painen_US
dc.subjectBreast canceren_US
dc.subjectIbandronateen_US
dc.subjectIntravenousen_US
dc.titlePhase II study of loading-dose ibandronate treatment in patients with breast cancer and bone metastases suffering from moderate to severe painen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu